CLAUDIA GOLDENSTEIN SCHAINBERG
Projetos de Pesquisa
Unidades Organizacionais
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Proceedings of the GRAPPA 2022 Executive Retreat(2023) NG, Beverly Cheok Kuan; JADON, Deepak; ADEBAJO, Adewale; AYAN, Gizem; DUFFIN, Kristina Callis; CHANDRAN, Vinod; COATES, Laura C.; D'AGOSTINO, Maria Antonietta; VLAM, Kurt de; DEODHAR, Atul; EDER, Lihi; GARG, Amit; GLADMAN, Dafna D.; GOEL, Niti; GOTTLIEB, Alice B.; HUSNI, M. Elaine; KATZ, Arnon; KAVANAUGH, Arthur; LUBRANO, Ennio; MEASE, Philip J.; MEROLA, Joseph F.; NASH, Peter; OGDIE, Alexis; PENNINGTON, Stephen R.; PEREZ-CHADA, Lourdes M.; PROFT, Fabian; ROSEN, Cheryl F.; SAVAGE, Laura; GOLDENSTEIN-SCHAINBERG, Claudia; SIEBERT, Stefan; SORIANO, Enrique R.; STEINKOENIG, Ingrid; TILLETT, William; ARMSTRONG, April W.; FITZGERALD, OliverThe Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) leadership congregated for a strategic planning meeting before the 2022 GRAPPA annual meeting in New York, USA. Meeting aims were to review GRAPPA's performance in relation to its 2016 goals and identify successes and areas for further improvement, identify key GRAPPA priorities and activities for the next 5 years, and explore committee structures to best support these aims.
- Bone erosions associated with systemic bone loss on HR-pQCT in women with longstanding polyarticular juvenile idiopathic arthritis(2023) RIBEIRO, Surian Clarisse C. R.; SALES, Lucas P.; FERNANDES, Alan L.; PEREZ, Mariana O.; TAKAYAMA, Liliam; CAPARBO, Valeria F.; ASSAD, Ana Paula L.; AIWAKA, Nadia E.; GOLDENSTEIN-SCHAINBERG, Claudia; BORBA, Eduardo F.; DOMICIANO, Diogo S.; FIGUEIREDO, Camille P.; PEREIRA, Rosa M. R.Objectives: To analyze longstanding polyarticular juvenile idiopathic arthritis (pJIA) for possible associations between localized bone damage (erosions), and systemic bone loss. Besides, to compare the systemic bone mass of pJIA with healthy controls. Methods: Thirty-four pJIA women and 99 healthy controls (HC) were included. Radius and tibia of all subjects were scanned by HR-pQCT. Volumetric bone mineral density (vBMD), bone microarchitecture, and -finite element parameters were analyzed. Patients underwent HR-pQCT of 2nd and 3rd metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints of the dominant hand, for bone erosions quantification. Results: The mean age of patients was 31.5 +/- 7.4yrs with a mean disease duration of 21.7 +/- 9.2yrs. Bone erosions were detectable in 79% of patients. The number of bone erosions was positively correlated with cortical porosity (Ct.Po) at tibia (r = 0.575, p = 0.001), and radius (r = 0.423, p = 0.018); and negatively correlated with cortical vBMD at tibia (r=-0.420, p = 0.015). In a logistic regression analysis, adjusted for anti-CCP, the presence of bone erosions was independently associated with Ct.Po at radius (p = 0.018) and cortical vBMD at tibia (p = 0.020). Moreover, cortical and trabecular vBMD, trabecular number, and mu-finite element parameters were decreased in patients compared to HC (p < 0.05). Conclusion: Bone erosions in longstanding pJIA women were associated with decreased cortical bone parameters, and these patients showed systemic bone impairment at peripheral sites compared with healthy controls.
- Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations(2023) LEUNG, Ying-Ying; KOROTAEVA, Tatiana V.; CANDIA, Liliana; PEDERSEN, Susanne Juhl; MOLANO, Wilson Bautista; RUDERMAN, Eric M.; BISOENDIAL, Radjesh; PEREZ-ALAMINO, Rodolfo; OLSDER, Wendy; MOELLER, Burkhard; GRAZIO, Simeon; GUDU, Tania; MODY, Girish M.; PINEDA, Carlos; RAFFAYOVA, Helena; ROHEKAR, Sherry; GOLDENSTEIN-SCHAINBERG, Claudia; URENA, Sergio R. Gutierrez; VARGAS, Julio Cesar Casasola; MEGHNATHI, Bhowmik; PRASAD, Roopa; RICHETTE, Pascal; MIRANDA, Jose Roberto S.; MALLIOTIS, Nikolas; LINDQVIST, Ulla; SIMON, David; EZEONYELI, Amara; SORIANO, Enrique R.; FITZGERALD, OliverObjective. We aimed to compile evidence for the efficacy and safety of therapeutic options for the periph-eral arthritis domain of psoriatic arthritis (PsA) for the revised 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations. Methods. A working group consisting of clinicians and patient research partners was convened. We reviewed the evidence from new randomized controlled trials (RCTs) for PsA treatment from February 19, 2013, to August 28, 2020. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-informed approach to derive evidence for the classes of therapeutic options for 3 patient groups: (1) naive to treatment, (2) inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and (3) inadequate response to biologic DMARDs (bDMARDs). Recommendations were derived through consensus meetings. Results. The evidence review included 69 RCTs. We derived GRADE evidence for each class of therapeutic options and achieved consensus for the recommendations. For patients naive to treatment, the working group strongly recommends csDMARDs (methotrexate, sulfasalazine, leflunomide) and phosphodi-esterase 4 inhibitors, and emphasizes regular assessment and early escalation to achieve treatment target. bDMARDs (tumor necrosis factor inhibitors [TNFi], interleukin 17 inhibitors [IL-17i], IL-12/23i, IL-23i) and Janus kinase inhibitors (JAKi) are also strongly recommended. For patients with inadequate response to csDMARDs, we strongly recommend TNFi, IL-17i, IL-12/23i, IL-23i, and JAKi. For those who had prior experience with bDMARDs, we strongly recommend a second TNFi, IL-17i, IL-23i, and JAKi. The evidence supporting nonpharmacological interventions was very low. An expert panel conditionally recom-mends adequate physical activity, smoking cessation, and diet to control weight gain. Conclusion. Evidence supporting optimal therapy for the peripheral arthritis domain of PsA was compiled for the revised 2021 GRAPPA treatment recommendations.